A Randomized Phase III Double-Blind Trial Evaluating Selective COX-2 Inhibition In COX-2 Expressing Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Pemetrexed disodium and celecoxib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. It is not yet known whether
giving gemcitabine hydrochloride or pemetrexed disodium together with carboplatin is more
effective with or without celecoxib in treating non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying gemcitabine hydrochloride, pemetrexed
disodium, and carboplatin to compare how well they work when given together with celecoxib
or a placebo in treating patients with advanced non-small cell lung cancer.
White River Junction, VT
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.